⌘K
t
Creo Medical Group plc announced a change in its Nominated Adviser and Broker, effective immediately. Numis Securities Limited has been replaced by Deutsche Bank AG, London Branch. This change follows the acquisition of Numis Securities Limited's parent company by Deutsche Bank AG on 23 October 2023.
| Date | 30 Jun 2025 |
| Time | 07:00:03 |
| Category | Miscellaneous |
| ID | 8264O |
Creo Medical Group plc
("Creo", the "Company" or the "Group")
Change of Nominated Adviser
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that following the acquisition of Numis Securities Limited's parent company by Deutsche Bank AG on 23 October 2023 and its ongoing integration, its Nominated Adviser and Broker has changed from Numis Securities Limited to Deutsche Bank AG, London Branch with immediate effect.
For further information please contact:
|
Creo Medical Group plc |
||
|
Richard Craven, Company Secretary |
Via Walbrook PR |
|
|
|
|
|
|
Deutsche Numis (Nominated Adviser, sole Broker and Financial Adviser) Freddie Barnfield / Duncan Monteith / Sher Shah |
+44 (0)20 7260 1000 |
|
|
|
|
|
|
Walbrook PR Ltd |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
|
Paul McManus / Alice Woodings
|
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About Creo Medical
Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com